Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

79.02 +0.97 (+1.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,568,996
Open 78.11
Bid (Size) 77.70 (1)
Ask (Size) 79.23 (1)
Prev. Close 78.05
Today's Range 77.94 - 79.24
52wk Range 72.87 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.80%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire

Performance

YTD
-7.46%
-7.46%
1 Month
+1.44%
+1.44%
3 Month
+3.97%
+3.97%
6 Month
+0.03%
+0.03%
1 Year
-11.68%
-11.68%

More News

Read More
A Look Into Gilead Sciences Inc's Price Over Earnings
Via Benzinga
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Via InvestorPlace
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
Via Benzinga
Is NASDAQ:GILD suited for dividend investing?
Via Chartmill
3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
From Gilead Sciences, Inc.
Via Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Via Benzinga
Exposures Product Safety
J&J, Gilead, BMS: A look at undervalued dividend payers
Via MarketBeat
Gilead Sciences's Options: A Look at What the Big Money is Thinking
Via Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics
Via Benzinga
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Stocks Stall On November 21, 2023, As Systematic Flows Abate
Via Talk Markets
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
Via Benzinga
Exposures Product Safety
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
Via Investor's Business Daily
Where Gilead Sciences Stands With Analysts
Via Benzinga
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
Via Investor's Business Daily
Buying the dip in high-yield Gilead Sciences
Via MarketBeat
Exposures COVID-19
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.